Saxagliptin
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Diabetes Mellitus, Non-Insulin-Dependent
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Trial Timeline
Nov 1, 2012 → May 1, 2014
NCT ID
NCT01608724About Saxagliptin
Saxagliptin is a approved stage product being developed by AstraZeneca for Diabetes Mellitus, Non-Insulin-Dependent. The current trial status is completed. This product is registered under clinical trial identifier NCT01608724. Target conditions include Diabetes Mellitus, Non-Insulin-Dependent.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01608724 | Approved | Completed |
| NCT01552005 | Pre-clinical | Completed |
| NCT00935467 | Phase 1 | Completed |
| NCT00770302 | Phase 1 | Completed |
Competing Products
20 competing products in Diabetes Mellitus, Non-Insulin-Dependent